Skip to content

Finished goods at other companies

Pfizer logo
PfizerPFE
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Incyte logo
IncyteINCY
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.16B+18.1%
Enterprise value$2.08B+15.2%
P/S32.7×-16.7×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's finished goods?
Agios Pharmaceuticals (AGIO) reported finished goods of $3.92M in Q1 2026.
How has Agios Pharmaceuticals's finished goods changed year-over-year?
Agios Pharmaceuticals's finished goods decreased by 2.5% year-over-year, from $4.02M to $3.92M.